Literature DB >> 637641

Familial hyperkalemia, hypertension, and hyporeninemia with normal aldosterone levels. A tubular defect in potassium handling.

N Brautbar, J Levi, A Rosler, E Leitesdorf, M Djaldeti, M Epstein, C R Kleeman.   

Abstract

A 52-year-old man had hypertension, persistent hyperkalemia, and hyperchloremic metabolic acidosis; renal and adrenal functions were normal. Four other members of the family have the same findings. The patient's plasma aldosterone (PA) level was within normal range, though plasma renin activity (PRA) was undetectable. The ability to conserve sodium with increased endogenous aldosterone levels, and the inability to increase potassium excretion while exogenous mineralocorticoid (fludrocortisone acetate) was administered, indicated a distal tubular defect in potassium handling. Effective reduction of the hyperkalemia by K+ -Na+ exchange resin also corrected the acidosis and the hyperchloremia, suggesting that hyperkalemia may cause metabolic acidosis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 637641

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  10 in total

Review 1.  WNK kinases and renal sodium transport in health and disease: an integrated view.

Authors:  James A McCormick; Chao-Ling Yang; David H Ellison
Journal:  Hypertension       Date:  2008-01-22       Impact factor: 10.190

Review 2.  Emerging Features of Ammonia Metabolism and Transport in Acid-Base Balance.

Authors:  I David Weiner; Jill W Verlander
Journal:  Semin Nephrol       Date:  2019-07       Impact factor: 5.299

3.  Furosemide and dDAVP for the treatment of pseudohypoaldosteronism type II.

Authors:  G Erdoğan; D Corapçioğlu; M F Erdoğan; J Hallioğlu; A R Uysal
Journal:  J Endocrinol Invest       Date:  1997-12       Impact factor: 4.256

Review 4.  The WNKs: atypical protein kinases with pleiotropic actions.

Authors:  James A McCormick; David H Ellison
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

5.  A new locus on chromosome 12p13.3 for pseudohypoaldosteronism type II, an autosomal dominant form of hypertension.

Authors:  S Disse-Nicodème; J M Achard; I Desitter; A M Houot; A Fournier; P Corvol; X Jeunemaitre
Journal:  Am J Hum Genet       Date:  2000-06-22       Impact factor: 11.025

Review 6.  Distal potassium handling based on flow modulation of maxi-K channel activity.

Authors:  Aylin R Rodan; Chou-Long Huang
Journal:  Curr Opin Nephrol Hypertens       Date:  2009-07       Impact factor: 2.894

Review 7.  Type II pseudohypoaldosteronism. Report of a case and review of the literature.

Authors:  S Muhammad; Z M Mamish; J R Tucci
Journal:  J Endocrinol Invest       Date:  1994-06       Impact factor: 4.256

8.  A familial case of pseudohypoaldosteronism type II (PHA2) with a novel mutation (D564N) in the acidic motif in WNK4.

Authors:  Takashi Sakoh; Akinari Sekine; Takayasu Mori; Hiroki Mizuno; Masahiro Kawada; Rikako Hiramatsu; Eiko Hasegawa; Noriko Hayami; Masayuki Yamanouchi; Tatsuya Suwabe; Naoki Sawa; Yoshifumi Ubara; Takuya Fujimaru; Eisei Sohara; Uchida Shinichi; Junichi Hoshino; Kenmei Takaichi
Journal:  Mol Genet Genomic Med       Date:  2019-05-01       Impact factor: 2.183

9.  Mechanism of Hyperkalemia-Induced Metabolic Acidosis.

Authors:  Autumn N Harris; P Richard Grimm; Hyun-Wook Lee; Eric Delpire; Lijuan Fang; Jill W Verlander; Paul A Welling; I David Weiner
Journal:  J Am Soc Nephrol       Date:  2018-02-26       Impact factor: 14.978

10.  Pseudohypoaldosteronism: case report and discussion of the syndrome.

Authors:  D C Throckmorton; M J Bia
Journal:  Yale J Biol Med       Date:  1991 May-Jun
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.